
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Children with severe autism spectrum disorder (ASD) often wander away from their homes or other safe environments, placing themselves in harm's way. A new study reveals the effect wandering has on families with children who exhibit this behavior.






